Biomarkers. When we have diagnostic and treatment biomarkers everything will change, including the disease definition and name.This may be a reflection of the number of ppl w/Fukuda who also qualify for IOM or CCC; but it may be a reflection of the fact that they were all diagnosed by clinicians with expertise in ME.
We need ME in research because those are the tighter definitions.
Socially and politically its muddled, with problems and advantages with every label.
We will never get ME accepted as the common use label in the current social climate, though times change. We already have ME definitions dominating the better research.
CFS is particularly problematic given it leads to deep misunderstanding even in doctors.
So (hypothetically) suppose ME were caused by one kind of thing, and it was different attacks on muscarinic receptors. We might then wind up with Muscarinic Receptor Dysfunction Disease or something like that.